John Lee

John Lee is a highly accomplished physician-scientist who currently serves as the Chief Medical Officer at ImmunityBio, a position he has held since March 2019.1 With an extensive background in oncology and immunotherapy, Dr. Lee has dedicated his career to advancing cancer treatment and developing innovative therapies.

Education and Early Career

Dr. Lee's educational background includes:

• BS in Biology from Stanford University (1986-1990)
• MD from the University of Minnesota-Twin Cities (1990-1995)1

He began his academic career as an Associate Professor at the University of Iowa from 1995 to 2008.1

Professional Experience

Academic and Clinical Roles::

Dr. Lee has held several prestigious positions throughout his career:

• Full Professor at the University of South Dakota (2010-2016)
• Surgeon at Sanford Health (2008-2016), where he specialized in resecting large head and neck cancers and led investigator-initiated clinical trials1

Leadership in Biotechnology::

• Senior Vice President at NantKwest (May 2016-Present)
• Executive Director of the Chan Soon Shiong Institute of Molecular Medicine (2016-2018)1

Current Role at ImmunityBio

As Chief Medical Officer at ImmunityBio, Dr. Lee oversees all aspects of clinical development, including:

• Biostatistics
• Data Metrics
• Clinical Operations
• Pharmacovigilance
• External collaborations
• NK basic research and development1

Under his leadership, the company has achieved significant milestones, including:

• Obtaining FDA Breakthrough Designation for their lead product N-803, an IL-15 superagonist
• Developing more than 20 INDs in three years to enhance cancer treatment in immune oncology1

Expertise and Focus

Dr. Lee's work primarily focuses on:

• Improving cancer treatment
• Developing novel immune oncology treatments for various types of cancer
• Translating pre-clinical science into new clinical trials
• Overseeing regulatory strategies for trials and medical writing1

His extensive experience as both a surgeon and researcher has given him a unique perspective in the field of oncology, allowing him to bridge the gap between clinical practice and innovative research.